A citation-based method for searching scientific literature


List of co-cited articles
130 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
77

Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers.
Akihiko Yoshida, Koji Tsuta, Susumu Wakai, Yasuhito Arai, Hisao Asamura, Tatsuhiro Shibata, Koh Furuta, Takashi Kohno, Ryoji Kushima. Mod Pathol 2014
87
66

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.
Lynette M Sholl, Heather Sun, Mohit Butaney, Chengsheng Zhang, Charles Lee, Pasi A Jänne, Scott J Rodig. Am J Surg Pathol 2013
111
55

Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples.
Kurtis D Davies, Anh T Le, Jamie Sheren, Hala Nijmeh, Katherine Gowan, Kenneth L Jones, Marileila Varella-Garcia, Dara L Aisner, Robert C Doebele. J Thorac Oncol 2018
64
55

On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Lénaïg Mescam-Mancini, Sylvie Lantuéjoul, Denis Moro-Sibilot, Isabelle Rouquette, Pierre-Jean Souquet, Clarisse Audigier-Valette, Jean-Christophe Sabourin, Chantal Decroisette, Linda Sakhri, Elisabeth Brambilla,[...]. Lung Cancer 2014
80
44

Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
Christina I Selinger, Bob T Li, Nick Pavlakis, Matthew Links, Anthony J Gill, Adrian Lee, Stephen Clarke, Thang N Tran, Trina Lum, Po Y Yip,[...]. Histopathology 2017
30
44

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.
Ryma Benayed, Michael Offin, Kerry Mullaney, Purvil Sukhadia, Kelly Rios, Patrice Desmeules, Ryan Ptashkin, Helen Won, Jason Chang, Darragh Halpenny,[...]. Clin Cancer Res 2019
117
44

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Julien Mazières, Gérard Zalcman, Lucio Crinò, Pamela Biondani, Fabrice Barlesi, Thomas Filleron, Anne-Marie C Dingemans, Hervé Léna, Isabelle Monnet, Sacha I Rothschild,[...]. J Clin Oncol 2015
224
44

Testing for ROS1 in non-small cell lung cancer: a review with recommendations.
Lukas Bubendorf, Reinhard Büttner, Fouad Al-Dayel, Manfred Dietel, Göran Elmberger, Keith Kerr, Fernando López-Ríos, Antonio Marchetti, Büge Öz, Patrick Pauwels,[...]. Virchows Arch 2016
112
44

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.
Esther Conde, Ana Suárez-Gauthier, Amparo Benito, Pilar Garrido, Rosario García-Campelo, Michele Biscuola, Luis Paz-Ares, David Hardisson, Javier de Castro, M Carmen Camacho,[...]. PLoS One 2014
50
44

ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
968
33

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
Yoshiyuki Suehara, Maria Arcila, Lu Wang, Adnan Hasanovic, Daphne Ang, Tatsuo Ito, Yuki Kimura, Alexander Drilon, Udayan Guha, Valerie Rusch,[...]. Clin Cancer Res 2012
125
33

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
33

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C Heng, Suzanne E Dahlberg, Pasi A Jänne, Suman Verma,[...]. J Clin Oncol 2016
305
33

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
33

ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases.
Arne Warth, Thomas Muley, Hendrik Dienemann, Benjamin Goeppert, Albrecht Stenzinger, Philipp A Schnabel, Peter Schirmacher, Roland Penzel, Wilko Weichert. Histopathology 2014
71
33



Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa,[...]. N Engl J Med 2010
33

Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Jaclyn F Hechtman, Ryma Benayed, David M Hyman, Alexander Drilon, Ahmet Zehir, Denise Frosina, Maria E Arcila, Snjezana Dogan, David S Klimstra, Marc Ladanyi,[...]. Am J Surg Pathol 2017
174
33

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paul K Paik, Alexander Drilon, Pang-Dian Fan, Helena Yu, Natasha Rekhtman, Michelle S Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F Berger, Charles M Rudin,[...]. Cancer Discov 2015
363
33

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Reinhard Büttner, John R Gosney, Birgit Guldhammer Skov, Julien Adam, Noriko Motoi, Kenneth J Bloom, Manfred Dietel, John W Longshore, Fernando López-Ríos, Frédérique Penault-Llorca,[...]. J Clin Oncol 2017
219
33

Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.
Seung Eun Lee, Boram Lee, Mineui Hong, Ji-Young Song, Kyungsoo Jung, Maruja E Lira, Mao Mao, Joungho Han, Jhingook Kim, Yoon-La Choi. Mod Pathol 2015
73
33

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
33

Targeting ALK: Precision Medicine Takes on Drug Resistance.
Jessica J Lin, Gregory J Riely, Alice T Shaw. Cancer Discov 2017
217
33

ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
Akihiko Yoshida, Takashi Kohno, Koji Tsuta, Susumu Wakai, Yasuhito Arai, Yoko Shimada, Hisao Asamura, Koh Furuta, Tatsuhiro Shibata, Hitoshi Tsuda. Am J Surg Pathol 2013
110
33


Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, Shun Lu, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung-Ju Ahn, Toshiaki Takahashi,[...]. J Clin Oncol 2018
117
33

Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas.
Esther Conde, Susana Hernandez, Mario Prieto, Rebeca Martinez, Fernando Lopez-Rios. Expert Rev Mol Diagn 2016
28
33


Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers.
E Conde, B Angulo, E Izquierdo, L Paz-Ares, C Belda-Iniesta, M Hidalgo, F López-Ríos. Clin Transl Oncol 2013
20
33

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
Esther Conde, Susana Hernandez, Rebeca Martinez, Barbara Angulo, Javier De Castro, Ana Collazo-Lorduy, Beatriz Jimenez, Alfonso Muriel, Jose Luis Mate, Teresa Moran,[...]. J Thorac Oncol 2019
25
33

Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.
Lawrence J Jennings, Maria E Arcila, Christopher Corless, Suzanne Kamel-Reid, Ira M Lubin, John Pfeifer, Robyn L Temple-Smolkin, Karl V Voelkerding, Marina N Nikiforova. J Mol Diagn 2017
233
33

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
921
22

Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations.
Frédéric Dugay, Francisco Llamas-Gutierrez, Marjory Gournay, Sarah Medane, François Mazet, Dan Christian Chiforeanu, Emmanuelle Becker, Régine Lamy, Hervé Léna, Nathalie Rioux-Leclercq,[...]. Oncotarget 2017
17
22

Comprehensive histologic analysis of ALK-rearranged lung carcinomas.
Akihiko Yoshida, Koji Tsuta, Harumi Nakamura, Takashi Kohno, Fumiaki Takahashi, Hisao Asamura, Ikuo Sekine, Masashi Fukayama, Tatsuhiro Shibata, Koh Furuta,[...]. Am J Surg Pathol 2011
206
22

Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations.
Yen-Fu Chen, Min-Shu Hsieh, Shang-Gin Wu, Yih-Leong Chang, Jin-Yuan Shih, Yi-Nan Liu, Meng-Feng Tsai, Tzu-Hsiu Tsai, Chong-Jen Yu, James Chih-Hsin Yang,[...]. J Thorac Oncol 2014
51
22

Institutional implementation of clinical tumor profiling on an unselected cancer population.
Lynette M Sholl, Khanh Do, Priyanka Shivdasani, Ethan Cerami, Adrian M Dubuc, Frank C Kuo, Elizabeth P Garcia, Yonghui Jia, Phani Davineni, Ryan P Abo,[...]. JCI Insight 2016
200
22

RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
826
22

Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm.
Heounjeong Go, Dong-Wan Kim, Donghyun Kim, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo, Yung-Jue Bang, Doo Hyun Chung. J Thorac Oncol 2013
50
22

Immunohistochemical Detection of ROS1 Fusion.
Yuhua Su, Theodore Goncalves, Dora Dias-Santagata, Mai P Hoang. Am J Clin Pathol 2017
12
22

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
Rui Wang, Haichuan Hu, Yunjian Pan, Yuan Li, Ting Ye, Chenguang Li, Xiaoyang Luo, Lei Wang, Hang Li, Yang Zhang,[...]. J Clin Oncol 2012
314
22

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
22

Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR.
Ling Shan, Fang Lian, Lei Guo, Tian Qiu, Yun Ling, Jianming Ying, Dongmei Lin. PLoS One 2015
52
22

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.
William D Travis, Elisabeth Brambilla, Masayuki Noguchi, Andrew G Nicholson, Kim R Geisinger, Yasushi Yatabe, David G Beer, Charles A Powell, Gregory J Riely, Paul E Van Schil,[...]. J Thorac Oncol 2011
22

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
22

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
Justin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, Sheheryar Kabraji, Mark M Awad, Ryohei Katayama, Amanda Pawlak, Mari Mino-Kenudson, Beow Y Yeap, Gregory J Riely,[...]. Clin Cancer Res 2013
356
22


Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
A Vaishnavi, M Capelletti, A T Le, S Kako, M Butaney, D Ercan, S Mahale, K D Davies, D L Aisner, A B Pilling,[...]. Nat Med 2013
347
22

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
22


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.